NICE 'cash-back' deal unlikely to be the norm

The NHS 'cash-back' scheme for bortexomib (Velcade) approved by NICE last week is unlikely to become the norm, say experts.

For the first time, NICE approved NHS use of a drug under a response-rebate scheme. This means that if a patient shows no response to the drug, the manufacturer has to refund its cost to the NHS.

NICE said the scheme was only considered after being suggested by manufacturer Janssen-Cilag.

If response-rebate is to be considered in the future, it would have to be suggested by manufacturers and be approved in principle by the DoH.

A NICE spokesman said: 'There are a number of factors that might need to be considered, such as whether it would be clinically appropriate for continuation of treatment to be determined on the basis of an appropriate response measure and how well the response measure predicts actual health outcomes.'

The scheme applies to patients with multiple myeloma who have had one prior therapy and for whom blood marrow transplantation has failed or is unsuitable.

At first relapse, eligible patients can be given bortexomib. If they show a full or partial response they will be allowed to continue with the treatment, funded by the NHS.

If the patient fails to respond, treatment will stop and Janssen-Cilag will refund the NHS the cost of the drug, says NICE.

Richard Ley, spokesman for the Association of the British Pharmaceutical Industry, said the scheme was likely to be 'the exception, not the norm'.

'They can't all do it,' he said. 'The reason is that Velcade is in a peculiar position.'

Within a few weeks of use, doctors can identify markers to see if the drug is being effective.

rachel.liddle@haymarket.com

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

NHS Employers updates guidance for assessing COVID-19 risk in BAME staff

NHS Employers updates guidance for assessing COVID-19 risk in BAME staff

Updated guidance to help GP practices assess and mitigate the risk staff from black,...

PHE unable to confirm it will meet deadline for COVID-19 risk report

PHE unable to confirm it will meet deadline for COVID-19 risk report

Public Health England (PHE) has been unable to confirm if its report into how factors...

More than half of GP locums have seen a significant drop in income due to COVID-19

More than half of GP locums have seen a significant drop in income due to COVID-19

More than half of GP locums have experienced a significant fall in their income during...

How a GP helped develop a protective shield to cover patients needing CPR in the pandemic

How a GP helped develop a protective shield to cover patients needing CPR in the pandemic

Wiltshire GP Dr Lydia Campbell-Hill explains how she helped create a mini isolation...

GP practices can now sign up to new online PPE portal

GP practices can now sign up to new online PPE portal

GP practices will be able to register with the DHSC's new online PPE portal, which...

Fully-qualified GP workforce fell by 712 over the past year

Fully-qualified GP workforce fell by 712 over the past year

The fully-qualified GP workforce in England fell by 2.5%, losing 712 full-time equivalent...